Client Services : 949-340-7598
General & Sales : 949-472-8000
Study Management : 949-472-8080

Publications

Mosaic Laboratories has co-authored or been referenced in the following publications with pharmaceutical and biotechnology companies:

2017
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322.

ARTICLE
2017
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, et al.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Thorac Oncol. 2017 Jan;12(1):110-120.

ARTICLE
2016
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55.

ARTICLE
2016
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, et al.

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Cancer Sci. 2016 Oct; 107(10): 1465–1470.

ARTICLE
2016
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et al.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Can Res. 2016 Nov 15;22(22):5461-5471

ARTICLE
2016
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, et al.

Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Mol Imaging Biol. 2016 Jun;18(3):446-53.

ARTICLE
2015
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, et al.

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. J Nucl Med. 2015 Dec;56(12):1828-35.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, et al.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2015 Aug 20;33(24):2609-16.

ARTICLE
2015
AbbVie and Mosaic Laboratories (Referenced in Methods)

Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, et al.

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015 Oct;26(10):2173-9.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, et al.

Phase I Study of the HER3-targeted Antibody Patritumab (U3-1287) Combined with Erlotinib in Japanese Patients with Non-small Cell Lung Cancer. Lung Cancer. 2015 Jun;88(3):275-81.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, et al.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine, 2015 Mar; 2(3): 264-271.

ARTICLE
2015
Bayer and Mosaic Laboratories (Referenced in Methods)

Wong ALA, Lim JSJ, Sinha A, Gopinathan A, Lim R, Tan C-S, et al.

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. Journal of Translational Medicine, 2015 Feb; 13: 57.

ARTICLE
2014
Celldex Therapeutics and Mosaic Laboratories (Referenced in Methods)

Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet Kluger, Kevin B. Kim, Peter D. Boasberg, et al.

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Journal of Clinical Oncology,2014 Nov; 32(32):3659-3666.

ARTICLE
2014
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, et al.

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6.

ARTICLE
2014
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, et al.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2014 Sep 1;20(17):4449-58.

ARTICLE
2014
Millennium Pharmaceuticals and Mosaic Laboratories (Referenced in Methods)

Friedberg JW1, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al.

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 2014 Jan 1;32(1):44-50.

ARTICLE
2014
Celldex and Mosaic Laboratories (Referenced in Methods)

Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, et al.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014 Nov 10;32(32):3659-66.

ARTICLE
2014
Merck and Mosaic Laboratories

Sun A, Lam RL, Harman A, Pavlick AC, Herman GA, Dauffenbach LM, Kerfoot CA. Huang P, Demuth T and Iannone R.

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy. Global Journal of Medical Research (K) (2014) 14(1): 11-21.

ARTICLE
2015
Memorial Sloan Kettering and Mosaic Laboratories

D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al.

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015 Mar;46(3):357-65.

ARTICLE
2013
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al.

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE (2013) 8(7): e67583.

ARTICLE
2013
Abbott Biotherapeutics and Mosaic Laboratories (Referenced in Methods)

Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, et al.

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.

ARTICLE
2013
PharmaMar and Mosaic Laboratories

Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernández LF, Kerfoot CA, Galmarini CM.

Expression of XPG protein in human normal and tumor tissues. Int J Clin Exp Pathol. 2013; 6(2): 199–211

ARTICLE
2012
Merck and Mosaic Laboratories

Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach LM, Kerfoot CA.

Level of phosphohistone H3 among various types of human cancers. BMJ Open. 2012; 2(5): e001071

ARTICLE
2012
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Erickson-Miller CL, Pillarisetti K, Kirchner J, Figueroa DJ, Ottesen L, Martin AM, Liu Y, et al.

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer. 2012 Sep 11;12:405.

ARTICLE
2012
Telormedix and Mosaic Laboratories (Referenced in Methods)

Arentsen HC, Hulsbergen-Van de Kaa CA, Jansen CFJ, Maj R, Leoni LM, Oosterwijk E, Witjes JA

Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU International. 2011 Oct;108 (7): 1210–14.

ARTICLE
2011
GlaxoSmithKline and Mosaic Laboratories (Thanked in Acknowledgements)

Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al.

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Curr Pharm Des. Br J Haematol. Clin Cancer Res. 2011 May 15;17(10):3420-30.

ARTICLE
2011
Attenuon and Mosaic Laboratories (Thanked in Acknowledgements)

Mazar AP, Ahn RW, O’Halloran TV.

Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011;17(19):1970-8.

ARTICLE
2010
EMD Serono Research Institute and Mosaic Laboratories (Referenced in Methods)

Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al.

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Curr Pharm Des. Br J Haematol. 2010 May;149(4):537-49.

ARTICLE
2010
Attenuon and Mosaic Laboratories

Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA and Mazar AP.

An anti-urokinase receptor (uPAR) antibody (ATN-658) blocks prostate cancer invasion, migration, growth and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010 Oct;12(10):778-88

ARTICLE
2010
Proacta and Mosaic Laboratories (Referenced in Methods)

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, et al.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010 Feb 15;70(4):1573-84.

ARTICLE
2009
Vertex Pharmaceuticals and Mosaic Laboratories

Wang T, Duffy JP, Wang J, Halas S, Salituro FG, Pierce AC, Zuccola HJ, Black JR, Hogan JK, Jepson S, Shlyakter D, Mahajan S, Gu Y, Hoock T, Wood M, Furey BF, Frantz JD, Dauffenbach LM, Germann UA, Fan B, Namchuk M, Bennani YL, Ledeboer MW.

Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.

ARTICLE

Patents

Mosaic Laboratories has been referenced in the following patents and patent applications by pharmaceutical and biotechnology companies:

2012
Amgen and Mosaic Laboratories

Abraham Anderson, Kelly Oliner, Rui Tang, Elwyn Loh, Sarita Dubey

Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor (“hgf”) antibodies in esophageal and gastric cancer patients. International application number: PCT/US2012/054312

PATENT
2012
GlaxoSmithKline and Mosaic Laboratories

Auger KR, Dar MM, Fleming RA

Method of administration and treatment. Application number: US2012/044618

PATENT
2010
Telormedix and Mosaic Laboratories

Anderson A, Oliner K, Tang R, Loh E, Dubey S.

Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration. Application number: 20110319442

PATENT
2009
Proacta (Auckland Uniservices Limited) and Mosaic Laboratories

Patterson AV, Guise CP, Abbattista MR, Wilson WR, Smaill JB, Syddall S, Denny WA, Ashoorzadeh A.

Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein. Application number: PCT/NZ2009/000227

PATENT